Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Wyles

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
Therapeutic Advances in Infectious Disease|May 20, 2022
The use of technology-based adherence monitoring in the treatment of hepatitis C virusYeba H Adje, Kristina M Brooks, Jose R Castillo-Mancilla, et al.
Health & Justice|July 11, 2024
Hepatitis C-related knowledge and attitude among adults on probation in a large US cityMatthew S Minturn, Kevin F Kamis, David L Wyles, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 21, 2012
Structure of a hepatitis C virus RNA domain in complex with a translation inhibitor reveals a binding mode reminiscent of riboswitchesSergey M Dibrov, Kejia Ding, Nicholas D Brunn, et al.
Journal of Virology & Antiviral Research|November 24, 2015
Vitamin D Metabolites Inhibit Hepatitis C Virus and Modulate Cellular Gene ExpressionJulio A Gutierrez, Krysten A Jones, Roxana Flores, et al.
Open Forum Infectious Diseases|August 15, 2020
Use of a Standardized Dalbavancin Approach to Facilitate Earlier Hospital Discharge for Vulnerable Patients Receiving Prolonged Inpatient Antibiotic TherapyAxel A Vazquez Deida, Katherine C Shihadeh, Candice R Preslaski, et al.
Bioorganic & Medicinal Chemistry|July 2, 2011
Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replicationNadejda Valiaeva, David L Wyles, Robert T Schooley, et al.
Open Forum Infectious Diseases|February 3, 2022
Hepatitis C Testing and Linkage to Care Among Adults on Probation in a Large US CityKevin F Kamis, David L Wyles, Matthew S Minturn, et al.
AIDS (London, England)|July 12, 2013
High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimenEdward R Cachay, David L Wyles, Francesca J Torriani, et al.
Hepatology (Baltimore, Md.)|July 7, 2015
Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infectionAaron F Carlin, Paula Aristizabal, Qinghua Song, et al.
Alimentary Pharmacology & Therapeutics|May 1, 2020
Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherenceMark Sulkowski, Annie F Luetkemeyer, David L Wyles, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Therapeutic Advances in Infectious Disease|May 20, 2022
The use of technology-based adherence monitoring in the treatment of hepatitis C virusYeba H Adje, Kristina M Brooks, Jose R Castillo-Mancilla, et al.
Health & Justice|July 11, 2024
Hepatitis C-related knowledge and attitude among adults on probation in a large US cityMatthew S Minturn, Kevin F Kamis, David L Wyles, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 21, 2012
Structure of a hepatitis C virus RNA domain in complex with a translation inhibitor reveals a binding mode reminiscent of riboswitchesSergey M Dibrov, Kejia Ding, Nicholas D Brunn, et al.
Journal of Virology & Antiviral Research|November 24, 2015
Vitamin D Metabolites Inhibit Hepatitis C Virus and Modulate Cellular Gene ExpressionJulio A Gutierrez, Krysten A Jones, Roxana Flores, et al.
Open Forum Infectious Diseases|August 15, 2020
Use of a Standardized Dalbavancin Approach to Facilitate Earlier Hospital Discharge for Vulnerable Patients Receiving Prolonged Inpatient Antibiotic TherapyAxel A Vazquez Deida, Katherine C Shihadeh, Candice R Preslaski, et al.
Bioorganic & Medicinal Chemistry|July 2, 2011
Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replicationNadejda Valiaeva, David L Wyles, Robert T Schooley, et al.
Open Forum Infectious Diseases|February 3, 2022
Hepatitis C Testing and Linkage to Care Among Adults on Probation in a Large US CityKevin F Kamis, David L Wyles, Matthew S Minturn, et al.
AIDS (London, England)|July 12, 2013
High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimenEdward R Cachay, David L Wyles, Francesca J Torriani, et al.
Hepatology (Baltimore, Md.)|July 7, 2015
Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infectionAaron F Carlin, Paula Aristizabal, Qinghua Song, et al.
Alimentary Pharmacology & Therapeutics|May 1, 2020
Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherenceMark Sulkowski, Annie F Luetkemeyer, David L Wyles, et al.
Pageof 8